Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
17. Februar 2022 07:00 ET
|
Mindset Pharma Inc.
TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy
08. Februar 2022 07:30 ET
|
Mindset Pharma Inc.
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds
03. Februar 2022 07:30 ET
|
Mindset Pharma Inc.
Mindset’s Family 3 of next-generation psilocybin compounds have demonstrated low levels of activity at the 5-HT2A receptor and long half lives Advancing compounds into additional Proof of Concept...
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014
25. Januar 2022 07:00 ET
|
Mindset Pharma Inc.
TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
05. Januar 2022 07:00 ET
|
Mindset Pharma Inc.
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, and...
Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
04. Januar 2022 08:16 ET
|
Mindset Pharma Inc.
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma Recaps 2021 Milestones and Highlights
30. Dezember 2021 06:00 ET
|
Mindset Pharma Inc.
Evolving Pipeline of Psychedelic Compounds Focused on Improved Efficacy and Safety Advancing MSP-1014 as First Lead Drug Clinical Candidate to IND-Enabling Studies TORONTO, Dec. 30, 2021 ...
Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds
28. Dezember 2021 16:01 ET
|
Mindset Pharma Inc.
TORONTO, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma to Participate in Citi’s Psychedelic Drug Call Series on January 6th
15. Dezember 2021 07:30 ET
|
Mindset Pharma Inc.
TORONTO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma to Participate in Stifel GMP’s The Future of Healthcare Conference on December 8th
02. Dezember 2021 08:30 ET
|
Mindset Pharma Inc.
TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...